These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 28479240)

  • 1. Fesoterodine for the Treatment of Nocturnal Urgency in Patients with Overactive Bladder Syndrome: An Analysis of Responders and Nonresponders.
    Khusid JA; Weiss JP; Carlsson MO; Mangan EK
    J Urol; 2017 Nov; 198(5):1119-1123. PubMed ID: 28479240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of flexible dose fesoterodine in men and women with overactive bladder symptoms including nocturnal urinary urgency.
    Weiss JP; Jumadilova Z; Johnson TM; Fitzgerald MP; Carlsson M; Martire DL; Malhotra A
    J Urol; 2013 Apr; 189(4):1396-401. PubMed ID: 23159276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.
    Chapple C; Schneider T; Haab F; Sun F; Whelan L; Scholfield D; Dragon E; Mangan E
    BJU Int; 2014 Sep; 114(3):418-26. PubMed ID: 24552358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of fesoterodine on nocturia and quality of sleep in Asian patients with overactive bladder.
    Yokoyama O; Hiro S; Hotta S; Mogami S; Yamagami H
    Urology; 2014 Apr; 83(4):750-5. PubMed ID: 24518285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose Desmopressin and Tolterodine Combination Therapy for Treating Nocturia in Women with Overactive Bladder: A Double-blind, Randomized, Controlled Study.
    Rovner ES; Raymond K; Andruczyk E; Juul KV
    Low Urin Tract Symptoms; 2018 Sep; 10(3):221-230. PubMed ID: 28560762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
    Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
    BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
    Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
    BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial.
    Wagg A; Khullar V; Marschall-Kehrel D; Michel MC; Oelke M; Darekar A; Bitoun CE; Weinstein D; Osterloh I
    J Am Geriatr Soc; 2013 Feb; 61(2):185-93. PubMed ID: 23350833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
    Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
    BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age related pathogenesis of nocturia in patients with overactive bladder.
    Weiss JP; Blaivas JG; Jones M; Wang JT; Guan Z;
    J Urol; 2007 Aug; 178(2):548-51; discussion 551. PubMed ID: 17570424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
    DuBeau CE; Morrow JD; Kraus SR; Creanga D; Bavendam T
    Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
    Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
    BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment Satisfaction with Flexible-dose Fesoterodine in Patients with Overactive Bladder who were Dissatisfied with Previous Anticholinergic Therapy: A Multicenter Single-Arm Clinical Study.
    Choi JB; Cho KJ; Park WH; Lee DH; Kim YH; Cho IR; Yoon H; Kim YS; Kim JC
    Urol J; 2020 Jan; 17(1):97-101. PubMed ID: 30882160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can botox improve night-time overactive bladder symptoms in women?
    Miotla P; Cartwright R; Futyma K; Bogusiewicz M; Skorupska K; Winkler I; Rechberger T
    Neurourol Urodyn; 2017 Mar; 36(3):648-652. PubMed ID: 26915654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study).
    Herschorn S; Chapple CR; Abrams P; Arlandis S; Mitcheson D; Lee KS; Ridder A; Stoelzel M; Paireddy A; van Maanen R; Robinson D
    BJU Int; 2017 Oct; 120(4):562-575. PubMed ID: 28418102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity.
    Nitti VW; Rovner ES; Bavendam T
    BJU Int; 2010 May; 105(9):1268-75. PubMed ID: 19889062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of novel β
    Yoshida M; Takeda M; Gotoh M; Yokoyama O; Kakizaki H; Takahashi S; Masumori N; Nagai S; Hashimoto K; Minemura K
    Int J Urol; 2019 Mar; 26(3):369-375. PubMed ID: 30557916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of drug cessation after flexible-dose fesoterodine in patients with overactive bladder.
    Khullar V; Cardozo L; Kelleher CJ; Hall T; Ryan J; Ebel Bitoun C; Darekar A; Arumi D; Wagg A
    BJU Int; 2013 Oct; 112(6):820-9. PubMed ID: 23465055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?
    Goldman HB; Oelke M; Kaplan SA; Kitta T; Russell D; Carlsson M; Arumi D; Mangan E; Ntanios F
    Int Urogynecol J; 2019 Feb; 30(2):239-244. PubMed ID: 29600400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome.
    Nitti VW; Dmochowski R; Sand PK; Forst HT; Haag-Molkenteller C; Massow U; Wang J; Brodsky M; Bavendam T
    J Urol; 2007 Dec; 178(6):2488-94. PubMed ID: 17937959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.